Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples